Skip Navigation



Glycobiology Advance Access published online on September 8, 2004
Glycobiology, doi:10.1093/glycob/cwh148
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
15/2/119    most recent
cwh148v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Charnaux, N.
Right arrow Articles by Gattegno, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charnaux, N.
Right arrow Articles by Gattegno, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received June 8, 2004
Revised August 3, 2004
Accepted September 3, 2004

ORIGINAL ARTICLES

RANTES (CCL5) induces a CCR5-dependent accelerated shedding of syndecan-1 (CD138) and syndecan-4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD44

Nathalie Charnaux 1, Séverine Brule 1, Thomas Chaigneau 1, Line Saffar 1, Angela Sutton 1, Morgan Hamon 1, Catherine Prost 1, Nicole Lievre 1, Claudio Vita 2, and Liliane Gattegno 1*

1 Laboratoire de Biologie Cellulaire, Biothérapies Bénéfices et Risques, UPRES 3410, Université Paris XIII, 74, rue Marcel Cachin, 93017, Bobigny, France; Hôpital Jean Verdier, 93017, Bondy, et, France
2 CEA, Saclay, Département d'Ingénierie et d'Etudes des Protéines, 91191 Gif-sur-Yvette, France

* To whom correspondence should be addressed. E-mail: liliane.gattegno{at}jvr.ap-hop-paris.fr.


  Abstract

We recently demonstrated that RANTES forms complexes with CCR5, syndecan-1, syndecan-4 and CD44 expressed by human primary macrophages and that syndecan-1 and syndecan-4, but neither CD44 nor syndecan-2, coimmunoprecipitate with CCR5. Here, we show that RANTES directly binds, in a glycosaminoglycan-dependent manner, to syndecan-1, syndecan-4 and CD44. Moreover, RANTES accelerates the shedding of syndecan-1 and syndecan-4 ectodomains from HeLa cells expressing CCR5 and by contrast, has no effect on the constitutive shedding of CD44 from these cells. These accelerated sheddings are prevented by the MEK1/2 inhibitor, U0126, and by the protein kinase C inhibitor, bisindolylmaleimide I. This indicates that both, mitogen-activated protein kinase- and protein kinase C-dependent signaling pathways are involved in these RANTES-induced accelerated sheddings. RANTES also induces a decreased expression of syndecan-1 and syndecan-4 by HeLa cells expressing CCR5, and on contrary an increased expression of CD44 by these cells. By contrast, RANTES does neither accelerate the shedding of syndecan-1 and syndecan-4 ectodomains from HeLa cells lacking CCR5, nor change the syndecan-1-, syndecan-4-, and CD44- plasma membrane expressions of these cells. CCR5 is therefore involved in the RANTES-induced accelerated shedding of syndecan-1 and syndecan-4 ectodomains. Nevertheless, the fact that RANTES stimulates in Hela cells, expressing or lacking CCR5, the mRNA synthesis of syndecan-1 and syndecan-4, indicates that the molecular events which follow the synthesis of these PGs differ, according to the presence or not of CCR5. Finally, RANTES forms glycosaminoglycan-dependent complexes with the shed ectodomains of syndecan-1, syndecan-4 as well as with those of CD44. The role of these events, in the pathophysiology of RANTES, deserves further studies.

Keywords: RANTES; Proteoglycan; Syndecan-1; Syndecan-4; Shedding; Chemokine.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
B. K. Masouleh, G. B. Ten Dam, M. K. Wild, R. Seelige, J. van der Vlag, A. L. Rops, F. G. Echtermeyer, D. Vestweber, T. H. van Kuppevelt, L. Kiesel, et al.
Role of the Heparan Sulfate Proteoglycan Syndecan-1 (CD138) in Delayed-Type Hypersensitivity
J. Immunol., April 15, 2009; 182(8): 4985 - 4993.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Hayashida, P. D. Stahl, and P. W. Park
Syndecan-1 Ectodomain Shedding Is Regulated by the Small GTPase Rab5
J. Biol. Chem., December 19, 2008; 283(51): 35435 - 35444.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Hayashida, Y. Chen, A. H. Bartlett, and P. W. Park
Syndecan-1 Is an in Vivo Suppressor of Gram-positive Toxic Shock
J. Biol. Chem., July 18, 2008; 283(29): 19895 - 19903.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
M. Zoller, P. Gupta, R. Marhaba, M. Vitacolonna, and P. Freyschmidt-Paul
Anti-CD44-mediated blockade of leukocyte migration in skin-associated immune diseases
J. Leukoc. Biol., July 1, 2007; 82(1): 57 - 71.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
S. Brule, N. Charnaux, A. Sutton, D. Ledoux, T. Chaigneau, L. Saffar, and L. Gattegno
The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9
Glycobiology, June 1, 2006; 16(6): 488 - 501.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. B. Buck, P. M. Day, C. D. Thompson, J. Lubkowski, W. Lu, D. R. Lowy, and J. T. Schiller
Human {alpha}-defensins block papillomavirus infection
PNAS, January 31, 2006; 103(5): 1516 - 1521.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.